JPMorgan Says Sagility Shares Could Rise 30.6%, Maintains Buy Rating
JPMorgan's latest note sets a ₹58 price target, which the report says implies 30.8% upside. The headline attributes a potential 31% gain to Sagility's Chirok Health acquisition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.